Status:
COMPLETED
Formulation and Clinical Evaluation of Ethosomal and Liposomal Preparations of Anthralin in Psoriasis
Lead Sponsor:
Assiut University
Conditions:
Psoriasis Vulgaris
Eligibility:
All Genders
9-70 years
Phase:
PHASE4
Brief Summary
Psoriasis is a common immune mediated inflammatory skin disease characterized by red heavily scaled plaques. Anthralin (1,8-dihydroxy-9-anthrone) which was introduced over 80 years ago has shown excel...
Detailed Description
Psoriasis is a common immune mediated inflammatory skin disease characterized by red heavily scaled plaques. Anthralin (1,8-dihydroxy-9-anthrone) which was introduced over 80 years ago has shown excel...
Eligibility Criteria
Inclusion
- patients with mild to moderate, stable chronic plaque psoriasis.
Exclusion
- patients with severe psoriasis.
- Patients received any topical or systemic treatment for psoriasis one month before the start of the study.
Key Trial Info
Start Date :
November 30 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 15 2020
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT03348462
Start Date
November 30 2017
End Date
January 15 2020
Last Update
March 10 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Assiut University Hospital
Asyut, Egypt, 71526